Indeed, in an experimental model of inflammatory bowel disease, CBG reduced IL-1β and IFN-γ levels in inflamed colons [8], while in a model of Huntington’s disease, CBG was able to decrease the expression of TNF-α and interleukin 6 (IL-6) [12]. The gene discussed is IL6; the disease is inflammatory bowel disease.